Gilead to acquire Tubulis for up to 5 billion dollars
Gilead will acquire Germany-based Tubulis for up to 5 billion dollars. The deal adds a class of experimental cancer drugs to the firm's oncology pipeline.
Xurve View
洞察:
Xurve View
In a significant expansion of its oncology research, GILEAD SCIENCES INC announced on Tuesday that it will acquire Germany-based Tubulis GmbH for a deal valued at up to $5 billion. This strategic move is expected to bolster the United States drugmaker's pipeline with a highly sought-after class of experimental cancer treatments.
